Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. ACN
6. NVDA
7. IBM
8. PRIM
9. SPY
10. DPZ

Go back to Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus

Vertex (VRTX) PT Raised to $285 at SunTrust

January 31, 2020 6:40 AM EST

SunTrust analyst Robyn Karnauskas raised the price target on Vertex (NASDAQ: VRTX) to $285.00 (from $235.00) while maintaining a Buy rating following results.

The analyst commented, "Recent approval of VRTX's drug TRIKAFTA and strong early launch metrics de-risk CF revenues for VRTX, in our... More